Companies Directory

Onclusive is a world leader in media intelligence technology and services, dedicated to supporting PR, Communications, and Marketing professionals. We deliver leading-edge innovation, human expertise, and unmatched media reach in a suite of media management, monitoring, and analytics solutions that support every stage of the communications cycle. Our unified platform and services enable our customers to make fast, accurate, data-driven decisions about their communications and marketing strategies, allowing them to prove and improve their value.

Building India’s largest chain of digitally connected day care cancer centres making high quality cancer care accessible and affordable.

Building India’s largest chain of digitally connected day care cancer centres making high quality cancer care accessible and affordable.

Building India’s largest chain of digitally connected day care cancer centres making high quality cancer care accessible and affordable.

Dans le cadre de la réforme territoriale adoptée en 2015 qui a donné naissance à la région Occitanie, les Réseaux Régionaux de Cancérologie OncoLR et Oncomip ont fusionné pour donner naissance au réseau régional de cancérologie de la région Occitanie, Onco-Occitanie. En 2023, Onco-Occitanie devient le Dispositif spécifique Régional du Cancer du Cancer. Onco-Occitanie a pour ambition d’œuvrer pour optimiser l’organisation régionale, harmoniser et améliorer la qualité de la prise en charge des patients atteints de cancer quel que soit leur domicile dans la région Occitanie.

Oncode is a dynamic and flexible software engineering firm, delivering high quality products that meet our clients satisfaction. The result of our engineering process is a complete solution for complex problems, that uses the best technologies to pursuit our clients success in their business activities. The company focuses on the design, implementation and testing of challenging and innovative projects to make our customers even more competitive, using software and business strategies as tools to reach their ambitious goals. Visit our website at http://oncode.it

Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. Founded in 1995, Oncodesign Services mission’ is to contribute to the discovery of innovative therapies with unmet medical needs, in particular in oncology, inflammation and infectious diseases. From target identification, hit-to-lead and lead optimization to IND filing, Oncodesign Services support the R&D programs of customers globally (whether pharmaceutical companies, biotechs, public research institutions, etc.). Oncodesign Services offers a full spectrum of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology (including humanized models). This continuum enables, either as stand-alone (SOLO) or as integrated (DRIVE) programs, the drug discovery of small molecule, molecular radiotherapy and biologicals entities. As a pioneer in translational medicine to evaluate the efficacy of treatments, the company challenge relies on increasing throughput, minimizing timelines from bench to bedside while having a differential proposition of treatment for patients and therefore innovative science. For that, Oncodesign Services has been creating new technological pathways to find and select the best drug candidates. Oncodesign Services has BSL1, BSL2 and BSL3 laboratories and all sites maintain the full AAALAC international accreditation for our animal care and use program. Based in Dijon, France, in the heart of the university and hospital cluster, within the Paris-Saclay cluster and in Montreal, Canada, Oncodesign Services benefits from 15,000m² of fully equipped chemistry and biologic laboratories. Oncodesign Services has 230 employees in France, United Kingdom, Germany, Canada and the United States, with highly competent in discovery research and translational pharmacology.

Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. Founded in 1995, Oncodesign Services mission’ is to contribute to the discovery of innovative therapies with unmet medical needs, in particular in oncology, inflammation and infectious diseases. From target identification, hit-to-lead and lead optimization to IND filing, Oncodesign Services support the R&D programs of customers globally (whether pharmaceutical companies, biotechs, public research institutions, etc.). Oncodesign Services offers a full spectrum of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology (including humanized models). This continuum enables, either as stand-alone (SOLO) or as integrated (DRIVE) programs, the drug discovery of small molecule, molecular radiotherapy and biologicals entities. As a pioneer in translational medicine to evaluate the efficacy of treatments, the company challenge relies on increasing throughput, minimizing timelines from bench to bedside while having a differential proposition of treatment for patients and therefore innovative science. For that, Oncodesign Services has been creating new technological pathways to find and select the best drug candidates. Oncodesign Services has BSL1, BSL2 and BSL3 laboratories and all sites maintain the full AAALAC international accreditation for our animal care and use program. Based in Dijon, France, in the heart of the university and hospital cluster, within the Paris-Saclay cluster and in Montreal, Canada, Oncodesign Services benefits from 15,000m² of fully equipped chemistry and biologic laboratories. Oncodesign Services has 230 employees in France, United Kingdom, Germany, Canada and the United States, with highly competent in discovery research and translational pharmacology.

Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. Founded in 1995, Oncodesign Services mission’ is to contribute to the discovery of innovative therapies with unmet medical needs, in particular in oncology, inflammation and infectious diseases. From target identification, hit-to-lead and lead optimization to IND filing, Oncodesign Services support the R&D programs of customers globally (whether pharmaceutical companies, biotechs, public research institutions, etc.). Oncodesign Services offers a full spectrum of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology (including humanized models). This continuum enables, either as stand-alone (SOLO) or as integrated (DRIVE) programs, the drug discovery of small molecule, molecular radiotherapy and biologicals entities. As a pioneer in translational medicine to evaluate the efficacy of treatments, the company challenge relies on increasing throughput, minimizing timelines from bench to bedside while having a differential proposition of treatment for patients and therefore innovative science. For that, Oncodesign Services has been creating new technological pathways to find and select the best drug candidates. Oncodesign Services has BSL1, BSL2 and BSL3 laboratories and all sites maintain the full AAALAC international accreditation for our animal care and use program. Based in Dijon, France, in the heart of the university and hospital cluster, within the Paris-Saclay cluster and in Montreal, Canada, Oncodesign Services benefits from 15,000m² of fully equipped chemistry and biologic laboratories. Oncodesign Services has 230 employees in France, United Kingdom, Germany, Canada and the United States, with highly competent in discovery research and translational pharmacology.

Oncogen Pharma is a fully integrated research based pharmaceutical company with a global outlook towards cancer treatment. Based in Malaysia, it is one of the fastest growing Pharmaceutical companies in the country with the largest portfolio of Oncology products under development. Oncogen Pharma has established state of the art R&D facilities for developing Oncology APIs and formulations for regulated markets. The diversified and qualified technical team of top professionals from different parts of the world have deep experience & exposure of the development of strategic products for global markets. Driven by the mission to challenge the status quo by developing high barrier medicines to enhance the quality of life worldwide, Oncogen Pharma is committed to provide early access of affordable and high-quality medicine. While we appreciate your interest and engagement in Oncogen Pharma's page, we ask that you post, comment or share respectfully. We reserve the right to remove spam and engagement activities that directly or indirectly suggest slanderous, libelous, obscene, offensive and indecent remarks. The content of this page is also for informational purposes only and not intended to substitute professional medical advice.